ILLUMINA / GRAIL

Illumina completes the divestiture of GRAIL

Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced ...

Statement Regarding Illumina's Decision to Divest Grail

Illumina's decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality ...

Illumina Board of Directors approves spin-off of GRAIL

Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on ...

Illumina, Inc., and GRAIL, Inc., In the Matter of

The Federal Trade Commission filed an administrative complaint and authorized a federal court lawsuit to block Illumina's $7.1 billion proposed acquisition ...

Illumina's planned divestment of GRAIL approved by the European ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of ...

Illumina Announces Decision to Divest GRAIL

Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party ...

GRAIL Statement on Divestiture

On December 17, 2023, Illumina announced it will divest GRAIL through a third-party sale or capital markets transaction, consistent with the ...

ILLUMINA / GRAIL - European Commission

Today, the European Commission has approved, under the EU Merger Regulation ('EUMR'), Illumina's plan to divest GRAIL following the ...

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving ...

Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers.

Illumina-Grail - United States Court of Appeals for the Fifth Circuit

Edith Brown Clement, Circuit Judge: The Federal Trade Commission determined that Illumina, Inc.'s acquisition of Grail, Inc. violated Section 7 ...

US biotech Illumina faces potential $7bn loss from forced Grail sale

Illumina will retain a 14.5 per cent stake in Grail after the sale. The San Diego-headquartered biotech founded Grail and first spun if off in ...

Illumina wins Grail battle in blow to EU merger power - Reuters

U.S. gene sequencing company Illumina on Tuesday won its court fight against the European Union's investigation of its $7.1 billion purchase ...

Illumina Forms New Company to Enable Early Cancer Detection via ...

(NASDAQ:ILMN) today announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing ...

Illumina publicly files Form 10 registration statement ahead of ...

GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ: ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures ...

M.10188 - ILLUMINA / GRAIL - Competition case search

Searches for published decisions can be carried out under policy area, case number, title and date.

Illumina parts ways with Grail, with divestiture complete

Illumina has cut (nearly) all ties with the cancer blood test developer. The DNA sequencing giant has completed its spinoff of the company.

Illumina to divest cancer test maker Grail after antitrust battles | Reuters

Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and ...

The European Court of Justice Confirms Illumina-GRAIL Merger ...

The European Court of Justice Confirms Illumina-GRAIL Merger Was Wrongly Reviewed by the European Commission ... Latham reflects on ECJ judgment.

Illumina Must Release Records of Legal Advice for Grail Deal

Illumina Inc. must release records related to the legal advice its board received before deciding to close a $7 billion re-acquisition of ...

Roundup: Illumina's long goodbye to cancer test maker Grail

Illumina took a bold step in 2021 when it closed the $8 billion acquisition of Grail, maker of a multi-cancer early detection test, before ...